Cargando…

Subtenon Vs Intravitreal Triamcinolone injection in Diabetic Macular Edema, A prospective study in Chinese population

Objective: Purpose of this study was to validate that Subtenon (SB) Triamcinolone (TA) injection is an alternative to Intravitreal (IV) Triamcinolone (TA) injection for the treatment of diabetic macular edema (DME). Methods: Forty eyes were selected having DME due to type 1 or type 2 diabetes. All t...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Dawei, Zhu, Bijun, Zheng, Zhi, Zhou, Haidong, Sun, Xiaodong, Xu, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publicaitons 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121691/
https://www.ncbi.nlm.nih.gov/pubmed/25097510
_version_ 1782329261532643328
author Luo, Dawei
Zhu, Bijun
Zheng, Zhi
Zhou, Haidong
Sun, Xiaodong
Xu, Xun
author_facet Luo, Dawei
Zhu, Bijun
Zheng, Zhi
Zhou, Haidong
Sun, Xiaodong
Xu, Xun
author_sort Luo, Dawei
collection PubMed
description Objective: Purpose of this study was to validate that Subtenon (SB) Triamcinolone (TA) injection is an alternative to Intravitreal (IV) Triamcinolone (TA) injection for the treatment of diabetic macular edema (DME). Methods: Forty eyes were selected having DME due to type 1 or type 2 diabetes. All the patients were treated with photocoagulation. IVTA was administered in one eye and SBTA in following eye of same patient. Improvement in visual acuity, macular edema and intraocular pressure was assessed before treatment and on 2(nd), 4(th), 8(th) and 12(th) week after treatment. Results: After administration of IVTA, MVA was reduced from baseline value (0.805 ± 0.069Log/MAR) to (0.577 ± 0.091 Log/MAR, p<.001) at the end of treatment. Similar results were observed after SBTA administration. MVA was reduced from (0.814 ± 0.082Log/MAR) to (0.49 ± 0.080 Log/MAR, p<.001) at 12(th) week. After IVTA injection Central macular thickness was significantly reduced to (246.8 ± 25 µm, p<0.001) from (390.5 ± 17 µm). There were no significant (p=0.51) difference in both eyes receiving different routes of same treatment. After SBTA injection CMT was significantly reduced to lower values (241.5 ± 27 µm, p<0.001) from (394.4 ± 21 µm). Intraocular pressure after IVTA administration was high (2.32 ± 0.72 mm/Hg, p=0.04) as compared to baseline (1.82 ± 0.94 mm/Hg). Similar pattern was also seen after SBTA administration but to significant extent. Elevation of IoP was observed in both eyes. Conclusion: Subtenon Triamcinolone injection is an alternative to Intravitreal Triamcinolone Injection for Diabetic Macular Edema.
format Online
Article
Text
id pubmed-4121691
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Professional Medical Publicaitons
record_format MEDLINE/PubMed
spelling pubmed-41216912014-08-05 Subtenon Vs Intravitreal Triamcinolone injection in Diabetic Macular Edema, A prospective study in Chinese population Luo, Dawei Zhu, Bijun Zheng, Zhi Zhou, Haidong Sun, Xiaodong Xu, Xun Pak J Med Sci Original Article Objective: Purpose of this study was to validate that Subtenon (SB) Triamcinolone (TA) injection is an alternative to Intravitreal (IV) Triamcinolone (TA) injection for the treatment of diabetic macular edema (DME). Methods: Forty eyes were selected having DME due to type 1 or type 2 diabetes. All the patients were treated with photocoagulation. IVTA was administered in one eye and SBTA in following eye of same patient. Improvement in visual acuity, macular edema and intraocular pressure was assessed before treatment and on 2(nd), 4(th), 8(th) and 12(th) week after treatment. Results: After administration of IVTA, MVA was reduced from baseline value (0.805 ± 0.069Log/MAR) to (0.577 ± 0.091 Log/MAR, p<.001) at the end of treatment. Similar results were observed after SBTA administration. MVA was reduced from (0.814 ± 0.082Log/MAR) to (0.49 ± 0.080 Log/MAR, p<.001) at 12(th) week. After IVTA injection Central macular thickness was significantly reduced to (246.8 ± 25 µm, p<0.001) from (390.5 ± 17 µm). There were no significant (p=0.51) difference in both eyes receiving different routes of same treatment. After SBTA injection CMT was significantly reduced to lower values (241.5 ± 27 µm, p<0.001) from (394.4 ± 21 µm). Intraocular pressure after IVTA administration was high (2.32 ± 0.72 mm/Hg, p=0.04) as compared to baseline (1.82 ± 0.94 mm/Hg). Similar pattern was also seen after SBTA administration but to significant extent. Elevation of IoP was observed in both eyes. Conclusion: Subtenon Triamcinolone injection is an alternative to Intravitreal Triamcinolone Injection for Diabetic Macular Edema. Professional Medical Publicaitons 2014 /pmc/articles/PMC4121691/ /pubmed/25097510 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Luo, Dawei
Zhu, Bijun
Zheng, Zhi
Zhou, Haidong
Sun, Xiaodong
Xu, Xun
Subtenon Vs Intravitreal Triamcinolone injection in Diabetic Macular Edema, A prospective study in Chinese population
title Subtenon Vs Intravitreal Triamcinolone injection in Diabetic Macular Edema, A prospective study in Chinese population
title_full Subtenon Vs Intravitreal Triamcinolone injection in Diabetic Macular Edema, A prospective study in Chinese population
title_fullStr Subtenon Vs Intravitreal Triamcinolone injection in Diabetic Macular Edema, A prospective study in Chinese population
title_full_unstemmed Subtenon Vs Intravitreal Triamcinolone injection in Diabetic Macular Edema, A prospective study in Chinese population
title_short Subtenon Vs Intravitreal Triamcinolone injection in Diabetic Macular Edema, A prospective study in Chinese population
title_sort subtenon vs intravitreal triamcinolone injection in diabetic macular edema, a prospective study in chinese population
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121691/
https://www.ncbi.nlm.nih.gov/pubmed/25097510
work_keys_str_mv AT luodawei subtenonvsintravitrealtriamcinoloneinjectionindiabeticmacularedemaaprospectivestudyinchinesepopulation
AT zhubijun subtenonvsintravitrealtriamcinoloneinjectionindiabeticmacularedemaaprospectivestudyinchinesepopulation
AT zhengzhi subtenonvsintravitrealtriamcinoloneinjectionindiabeticmacularedemaaprospectivestudyinchinesepopulation
AT zhouhaidong subtenonvsintravitrealtriamcinoloneinjectionindiabeticmacularedemaaprospectivestudyinchinesepopulation
AT sunxiaodong subtenonvsintravitrealtriamcinoloneinjectionindiabeticmacularedemaaprospectivestudyinchinesepopulation
AT xuxun subtenonvsintravitrealtriamcinoloneinjectionindiabeticmacularedemaaprospectivestudyinchinesepopulation